Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy.

Trial Profile

Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Mologen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 May 2015 Results of a subgroup analysis on overall survival were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2013 Final results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top